the company commercialised a genetic test to determine whether a cow will produce milk without the a1 protein and to market a1 protein free milk initially a2 corporation focused on dairy farm breeding programs to develop herds that would produce only a1 protein free milk however the launch of a1 protein free milk was delayed by opposition from fonterra which had protected contracts under new zealand law with about 98 of new zealand dairy farms seeking leverage in the battle with fonterra over access to farmers and over patent rights paterson led the company into litigation against fonterra asking the new zealand high court to order fonterra to put health warnings on its conventional milk concerning risks of type 1 diabetes heart disease autism and schizophrenia due to the presence of a1 beta casein and to force fonterra to publicly disclose all the information it had about the links between a1 beta casein and health risks the litigation threatened new zealand s economy and international reputation as at the time fonterra was responsible for 20 of new zealand s exports the press over the litigation and public concern over the claims of a2 corporation led the new zealand food safety